Supplementary Materials

Supplementary Material for:

Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen–specific CTLs

Michael C. Brown, Eda K. Holl, David Boczkowski, Elena Dobrikova, Mubeen Mosaheb, Vidya Chandramohan, Darell D. Bigner, Matthias Gromeier,* Smita K. Nair*

*Corresponding author. Email: smita.nair{at} (S.K.N.); grome001{at} (M.G.)

Published 20 September 2017, Sci. Transl. Med. 9, eaan4220 (2017)
DOI: 10.1126/scitranslmed.aan4220

This PDF file includes:

  • Materials and Methods
  • Fig. S1. PVSRIPO cytotoxicity in malignant glioma cell lines.
  • Fig. S2. Flow cytometry analysis of DC phenotype in Fig. 3.
  • Fig. S3. Analysis of PVSRIPO infection of DCs.
  • Fig. S4. Flow cytometry analysis of DC phenotype in Fig. 5.
  • Fig. S5. Analysis of viral replication in DC/DM6 cocultures and PVSRIPO infection of human monocytes.
  • Fig. S6. Tumor antigen–specific CTL induction by PVSRIPO oncolysate–pulsed DCs in vitro.
  • Fig. S7. IFN-β production by mRIPO-infected and LPS-treated mouse DCs.
  • Fig. S8. Analysis of B16-F10.9-OVA-CD155 tumor homogenate and tumor-draining lymph nodes after mRIPO treatment.
  • Fig. S9. Analysis of tumor-infiltrating immune cells, myeloid cells, and monocytes/macrophages.
  • Fig. S10. Analysis of tumor-infiltrating immune cells.
  • Fig. S11. PVSRIPO-mediated tumor cytotoxicity, DC infection/stimulation, and antitumor immunity.
  • Table S1. Relevant functions of cytokines/proteins present in DM6 melanoma-conditioned AIM V medium.
  • References (6178)

[Download PDF]